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ABSTRACT 
PHOSPHORYLATION OF THE ESTROGEN RECEPTOR ALPHA (ERa) AT SERINE 
118 BY PHOSPHO-P44/42 MAPK AND REGULATION BY ESTROGEN AND 
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Tonia Lakisha Hermon 
Eastern Virginia Medical School, 2009 
Director: Dr. Frank J. Castora 
It is thought that the growth of uterine leiomyomas may be mediated by the 
interaction of estrogen receptor alpha (ERa) and growth factor pathways and that 
phosphorylation of ERa at serine 118 (ERa-phospho-Serl 18) is important in this 
interaction. In tissue, immunoblotting and immunohistochemistry were used to 
investigate the expression of ERa-phospho-Serl 18, phosphorylated p44/42 mitogen-
activated protein kinase (phospho-p44/42 MAPK), and proliferating cell nuclear antigen 
(PCNA) in human leiomyoma and myometrial tissues during the proliferative and 
secretory phases of the menstrual cycle. In vitro studies to assess proliferation of uterine 
leiomyoma (UtLM) and uterine smooth muscle (UtSMC) cells and expression of ERa-
phospho-Serl 18 and phospho-p44/42 MAPK were done using western blotting and a cell 
proliferation assay, respectively, after treatment with estrogen (E2) and progesterone (P4), 
or with the clinical compounds, raloxifene and asoprosnil in the presence and absence of 
the MAPK inhibitor, PD98059. The tissue studies showed that tumors taken from the 
proliferative phase expressed significantly higher levels of ERa-phospho-Serl 18, 
phospho-p44/42 MAPK, and PCNA compared to patient-matched myometrial samples 
and had significantly higher ERa-phospho-Serl 18 and PCNA expression compared to 
secretory phase tumors. Also, enhanced colocalization and association of phospho-
p44/42 MAPK and ERa-phospho-Serl 18 were observed in proliferative phase tumors by 
confocal microscopy and immunoprecipitation, respectively. The in vitro studies showed 
that ERa-phospho-Serl 18 and phospho-p44/42 MAPK protein expression levels are 
increased in UtLM cells in a prolifeative phase versus secretory phase hormonal milieu 
and are reduced in UtLM cells after treatment with PD98059 in the proliferative phase. 
Also, the in vitro studies showed more interaction and co-expression of ERa-phospho-
Serl 18 and phospho-p44/42 MAPK proteins in leiomyoma cells treated with proliferative 
versus secretory phase hormones. These in vitro studies demonstrated that in uterine 
leiomyoma cells phospho-p44/42 MAPK phosphorylates ERa at serine 118 and this 
phosphorylation is increased when leiomyoma cells are treated with the proliferative 
phase (E2 predominant) hormones. Increased proliferation and enhanced ERa-phospho-
Serl 18 expression was observed in UtLM cells following treatment with E2. Also, the 
clinical compound raloxifene, but not asoprisnil was found to inhibit E2-induced 
leiomyoma cell growth in part by decreasing phosphorylation of ERa at serine 118. 
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CHAPTER I 
INTRODUCTION AND BACKGROUND 
Uterine leiomyomas (fibroids; myomas) are one of the most common benign 
gynecologic tumors in women of reproductive age. These tumors represent a significant 
public health problem since they are responsible for approximately 200,000 
hysterectomies per year and are the leading cause of hysterectomy in the United States [4, 
29, 72]. Fibroids have also been associated with clinical disease with moderate to high 
frequency not only in women in the United States, but also in women in Europe [55], 
Africa [28], and Japan [60]. 
Uterine leiomyomas tend to grow during the reproductive years, but regress after 
menopause, suggesting that these tumors are hormonally regulated [20]. The ovarian 
steroid hormones, estrogen and progesterone, are believed to play an important role in the 
growth of uterine leiomyomas [20,48, 57]; however, there is increasing evidence that sex 
steroids are not the only modulators of leiomyoma growth [29,48]. Studies have shown 
that circulating steroid hormone levels are similar in women that have or do not have 
leiomyomas, indicating that specific local, tissue-regulated factors may be involved in the 
pathogenesis of these tumors [12]. The heterogeneity of leiomyoma growth within a 
given uterus, despite identical exposure of these tumors to similar circulating sex steroid 
concentrations, suggests the involvement of local cytokines and/or growth factors [13, 
48]. 
The model journal for this dissertation is Virchows Archiv. 
2 
Estrogen exerts its physiological effects by binding to estrogen receptor alpha and 
beta (ERa and |3). In addition to the traditional ERa activation (hormone binding), this 
receptor can be activated by growth factor signaling pathways via phosphorylation of the 
ERa at specific serines [24, 42]. In human breast cancer cells, it has been shown that in 
the presence or absence of estradiol binding, human ERa is predominately 
phosphorylated on Ser-118 and to lesser extent on Ser-104 and Ser-106 [11, 15, 42]. 
Phosphorylation of ERa influences its activity and may lead to ERa mediated 
transcription. Prior to our recent publication [32] there were no studies that had reported 
the role of phosphorylation of ERa at Ser-118 in human or rodent uterine leiomyomas. 
Progesterone has also been shown to be involved in fibroid growth, having both 
inhibitory and stimulatory effects on their growth [16, 18, 19, 46]. Evidence shows that 
progesterone can induce leiomyoma cell proliferation and up-regulate the growth factor, 
epidermal growth factor (EGF) [61]. Progesterone has also been shown to down-regulate 
insulin-like growth factor-I (IGF-I) mRNA and protein expression in cultured leiomyoma 
cells [76]. There is also considerable biological evidence for "crosstalk" between the 
estrogen and progesterone hormone receptor signaling pathways [40]. In many cases, 
progestins suppress the stimulatory effects of estrogens in target tissues although estrogen 
upregulates the progesterone receptor [37,41]. In a study using tissue from women with 
endometrial hyperplasia, which is also a hormonally regulated disease, ERa protein 
expression was down regulated after use of the progestins, levonorgestrel and 
medroxyprogesterone [69]. The mechanisms involved in the "crosstalk" between the 
progesterone and estrogen hormone receptor pathways and how they interact with growth 
factor receptor pathways, have not been fully elucidated in uterine leiomyomas. 
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Studies have indicated that hormones and growth factor signaling pathways are 
mediators of leiomyoma growth [29,48, 64]. In uterine leiomyoma cell cultures, the 
mitogen activated protein kinase (MAPK) pathway interacts with the estrogen system via 
the ER [3]. Constitutively activated MAPK (phospho-p44/42 MAPK) is highly 
expressed in leiomyoma and myometrial tissue and is increased in leiomyomas compared 
to normal myometrial tissue [14]. A study has indicated, that MAPK activity increases in 
leiomyoma cells after treatment with estradiol and that an indirect interaction between the 
ER and growth factor pathways due to increased secretion of platelet-derived growth 
factor (PDGF) and activation of the MAPK pathway in uterine leiomyoma cells treated 
with estradiol [3]. In breast cancer cells, phosphorylation of ERa at Ser-118 occurs in 
response to activation of MAPK (phospho-p44/42) [3, 36,42]. To date, there is only one 
reported study [32] that addresses the mechanisms by which phosphorylation of ERa can 
occur via growth factor pathways in fibroids. However, the specific molecular 
mechanism(s) by which phosphorylation occurs remains to be explored. 
Currently the main non-invasive medical treatment for fibroids is GnRH 
(Gonadotropin releasing hormone) agonists, which can only be used temporarily due to 
major side effects such as bone loss and other major symptoms of menopause. New 
potentially promising medicinal treatments for leiomyomas are SERMs (Selective 
Estrogen Receptor Modulators) and SPRMs (Selective Progesterone Receptor 
Modulators), which are a novel class of non-steroidal therapeutic drugs (raloxifene is a 
SERM and asoprisnil is a SPRM) [20]. Promising clinical and preclinical studies have 
shown that hormonal modulation by raloxifene (SERM) and asoprisnil (SPRM) may 
provide a novel treatment approach for fibroids. 
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SERMs are non-steriodal estrogen receptor ligands that act as estrogens in some 
tissues while blocking estrogen action in others. Raloxifene is a new class of SERMs 
with unique properties. Raloxifene acts as an estrogen antagonist in the breast and the 
uterus and as an estrogen agonist in bone and lipids. Raloxifene was found to 
significantly reduce leiomyoma size in post-menopausal women without affecting the 
endometrium. Jirecek et al. and others have demonstrated that treatment with raloxifene 
also inhibits leiomyoma growth in premenopausal women [35, 53]. Little information is 
available regarding the specific mechanisms by which raloxifene can causes shrinkage of 
leiomyomas. 
SPRMs are progesterone receptor ligands that exert clinically relevant tissue-
selective progesterone agonist, antagonist, partial, or mixed agonist/antagonist activity, 
and therefore have the potential to exhibit the beneficial effects of progestins and 
progesterone antagonists, while avoiding their drawbacks. Asoprisnil is a SPRM that was 
recently in clinical trials for treatment of uterine fibroids and endometriosis. In a 
placebo-controlled study using Asoprisnil, leiomyoma volume was reduced and the 
duration and intensity of uterine bleeding was suppressed [52]. This report suggests that 
Asoprisnil, would be a suitable SPRM candidate to use in this proposed study to elucidate 
the mechanisms involved in how asoprisnil affects fibroid growth. 
Little information is available regarding the precise molecular mechanisms by 
which raloxifene and asoprisnil cause shrinkage of leiomyomas. A better understanding 
of the pathways involved in the actions of raloxifene and asoprisnil on leiomyomas will 
contribute to the effective and safe use of these compounds for the treatment of fibroids. 
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Uterine Leiomyomas 
Uterine leiomyomas (fibroids; myomas) are one of the most common benign 
tumors that arise from individual smooth muscle cells of the uterus in woman of 
reproductive age [29, 72]. These tumors are monoclonal; that is, each fibroid originates 
from a single smooth muscle cell. Fibroids are the leading cause of hysterectomy in the 
United States and represent a significant public health problem. The clinically 
symptomatic tumors occur in 25-30% of American women; however, these tumors have 
been found to occur in up to 77% of women randomly sampled for pathologic 
examination of their uteri. The prevalence of uterine myomas varies with age, race, and 
diagnostics modality. It has been reported that leiomyomas are more likely to be 
diagnosed in black women than white women [10,23, 47]. In a random sample of US 
women, aged 35-49 years, the cumulative incidence of myomas by the age of 50 was 
>80% for black women and approached 70% for white women as diagnosed by review of 
surgical specimens and /or ultrasonography [65]. 
Fibroids can vary is size from the size of a pea to that of a football [1]. These 
tumors can also grow in different areas of the uterus, which is shown below in Fig. 1 
[58]. The location of the fibroid seems to be more important than size in determining 
symptoms. Symptoms attributable to myomas can generally be classified in three distinct 
categories: abnormal bleeding, pelvic pressure and pain, and reproductive dysfunction 
[63]. Leiomyomas in the anterior position of the uterus can cause urinary symptoms 
(excessive urination) and those in the posterior position can cause constipation. 
Pedunculated submucosal 
Intramural 
Submucosal^ 
Kg. 1 Sagittal section of a uterus with fibroids. Pedunculated fibroids protrude into the abdominal cavity or 
uterine lumen (yellow tumors). Intramural fibroids occur within the wall of the uterus (green tumor). 
Submucosal fibroids lie adjacent to the mucosa (inner lining of the uterus, blue tumor)) and subserosal fibroids 
lie beneath the serosa (outer lining of the uterus, purple tumors). 
Leiomyomas often contain a large amount of fibrous connective tissue and extracellular 
matrix components such at collagen, fibronectin and glycoaminoglycans that can 
constitute a significant proportion of the tumor mass [29]. Fibroids have also been found 
to have 50% more extracellular matrix (ECM) compared to that of the corresponding 
myometrium [30]. The overproduced ECM in fibroids plays an important role in the 
metabolic processes leading to tumor growth by serving as a repository for biologically 
active growth factors and cytokines, such as TGFp [34]. Release of growth factors and 
cytokine from ECM storage can change the activity of the factors, which, in turn control 
cell proliferation and remodeling of the ECM and adjacent tumor cells [29]. 
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Treatment of fibroids depends upon clinical symptoms and signs, location and 
presentation of the tumors, the patient's age, parity, desire for future pregnancies and 
overall general health [1]. Invasive surgical treatments such as hysterectomy and 
myomectomy have long been the main modes of therapy for leiomyomas [1, 63]. 
Hysterectomy (abdominal, laparoscopic) eliminates both the symptoms and the chance of 
recurrence; however, this option is not suitable for women who desire future pregnancies 
and who wish to retain their uteri for other reasons. Another widely performed surgical 
treatment is myomectomy (abdominal, laparoscopic, hysteroscopic) [9, 31, 70]. The 
disadvantage of myomectomy is the risk that new fibroids will form in the intact uterus 
[63]. Other invasive modalities of treatment for fibroids include uterine artery 
embolization (UAE) and MRI-guided cryomyolysis [9, 21, 22, 67]. 
GnRH (Gonadotropin releasing hormone) agonists are the main non-invasive 
medical treatment for leiomyomas. They work by initially increasing the release of the 
gonadotropins (luteinizing hormone [LH] and follicle stimulating hormone [FSH]), which 
is followed shortly by desensitization and down regulation to a hypogonadotropic 
hypogonadal state clinically resembling menopause with regression of the tumor mass 
[63]. Once this treatment is discontinued the fibroids tend to return to pretreatment size. 
Treating fibroids with GnRH agonists can cause unwanted side effects in other estrogen-
responsive target organs, such as bone, which makes long-term use of GnRH agonists not 
practical. SERMs and SPRMs has been shown to be promising medicinal treatments for 
fibroids (tamoxifen and raloxifene are SERMs and asoprisnil is a SPERM) [20]. Clinical 
and preclinical studies have shown that hormonal modulation by SERMs may provide a 
novel treatment approach for uterine leiomyoma [53, 54, 56, 73]. A study involving the 
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administration of GnRH agonist and raloxifene to premenopausal women with 
symptomatic uterine fibroids reported the prevention of GnRH agonist related bone loss. 
Studies aimed at understanding the mechanisms involved in leiomyoma growth are 
essential to developing targeted therapeutic strategies [53]. 
The Steroid Hormones Estrogen and Progesterone and Classical Binding to their 
Receptors 
Steroid hormones all have a chemical structure based on the steroid nucleus and 
are derived from cholesterol. Estrogen and Progesterone are steroid compounds that are 
synthesized and secreted by endocrine cells and may travel via the blood stream to their 
target cells to bind to specific receptors (ER and PR) [68]. Also, these steroid hormones 
may act on other target cells in their vicinity or on the same cell in which they are 
produced without leaving the cell or after their release and subsequent binding to 
receptors in or on the cell. The steroid hormone receptors are transcription factors that 
are members of the ligand activated nuclear receptor superfamily. The structure of these 
receptors can be divided into five domains: A, B, C, D, and E [43, 68]. The A/B domain, 
located at the N-terminal, is highly variable in sequence and length and contains a 
transactivation function. The C region is involved in DNA recognition and dimerization. 
The hinge region (D region) allows the protein to bend or alter conformation, and often 
contains a nuclear localization domain. The ligand-binding domain (LBD - E region) is 
functionally complex and usually contains regions important for heat-shock protein 
association, dimerization, nuclear localization, transactivation and ligand binding. Once 
these receptors are activated by their ligand they form heterodimers that bind to their 
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responsive elements (ERE & PRE) in the cell's DNA to exert its effect [68]. The ER and 
PR are expressed in leiomyoma cells and tissues [46]. 
There are two isoforms of the ER, known to date: ERa and ER(J with a molecular 
weight (MW) around 66 and 60 kilodaltons (kD), respectively [8]. Both receptors are 
expressed in uterine leiomyomas and myometrium during all phases of the menstrual 
cycle. ERa has been shown to be greater than ERfJ in non-pregnant women, and high 
levels of ER($ are expressed in term myometrium [2]. ERa is primarily expressed in the 
uterus, liver, kidney, and heart, whereas ER|3 is expressed primarily in the ovary, 
prostate, lung, gastrointestinal tract, bladder, and hematopoietic and central nervous 
system of humans and animals [20, 49]. Binding of a ligand to ER triggers 
conformational changes in the receptor and this leads, via a number of events (i.e... 
receptor dimerization, receptor-DNA interaction, recruitment of and interaction with 
coactivators and other transcription factors, and formation of a reinitiating complex), to 
changes in the rate of transcription of estrogen-regulated genes. 
The human progesterone receptor exists as two isoforms (PR-A, MW = 94kD, 
PR-B, MW =120 kD), which are derived from a single gene [43, 62]. The human A 
form is a truncated version of the B form lacking the amino-terminal 165 amino acids of 
human PR-B [75]. PR-B functions as a transcriptional activator of P4-responsive genes, 
whereas PR-A may function as a transcriptional inhibitor [16]. Both, PR-A and PR-B are 
significantly increased in leiomyoma compared to adjacent myometrium [51, 71]. 
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Estrogen Receptor Phosphorylation 
Both the estrogen receptors are activated by binding of the ligand, E2 and by 
phosphorylation. In vitro studies using Cos-1 and Hela cells suggest that murine ERa is 
phosphorylated at serine 60 by the MAPK pathway [66]. Phosphorylation of ERa has 
been extensively studied and its phosphorylation at serine (104, 106 and 118) and 
tyrosine residues [42]. Phosphorylation of ERa is enhanced in response to E2 binding 
and through the activation of growth factor signaling pathways such as the MAPK 
pathway [11, 36, 42]. The most widely studied phosphorylation site on ERa is serine 
118. There is a large body of in vivo and in vitro evidence that show ERa is 
phosphorylated at Ser 118 in the presence or absence of estradiol. In breast cancer cells 
and calf uterine tissue estradiol binding induced immediate phosphorylation of the 
estrogen receptor at Ser 118 and activation of the receptor [24]. Some in vivo studies 
using Cos-1 (African green monkey kidney cells) and SK-Br-3 (Human breast cancer 
cells) cells showed that p44/42 MAPK directly phosphorylates ERa at ser 118 [11]. E2 
was found to induce phosphorylation of ERa at serine 118 in an endometrial cancer cell 
line [44]. Due to the phosphorylation of ERa in hormonally regulated diseases (breast 
and endometrial cancers) like fibroids, phosphorylation of ERa at serine 118 may be 
highly expressed in human uterine leiomyomas and may play a role in their growth. 
Progesterone and the Estrogen Receptor 
The estrogen and progesterone hormone receptor signaling pathways have been 
shown to interact with each other. In many cases, progestins (synthetic forms of 
progesterone) have been shown to suppress the stimulatory effects of estrogens in target 
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tissues [37, 41]. In the rat uterus progestins blocked the increased expression of estrogen-
induced genes [40]. Also, liganded PR-A and PR-B can suppress estradiol-stimulated ER 
activity in rat uterine cells. In rat uterine leiomyoma cells, PR ligand suppresses ER 
signaling. Progesterone has been shown to have a direct affect on ERa expression [33, 
41]. Progesterone has been shown to have a negative effect on ERa expression [33, 41], 
and ERa expression has been reported to be higher in myometrial and leiomyoma tissue 
from women in the proliferative (E2 dominant) versus secretory (P4 dominant) phase of 
the menstrual cycle based on immunohistochemisty and western blotting. The 
mechanisms involved in the crosstalk between the progesterone and estrogen hormone 
pathways have not been fully studied in leiomyomas. In human uterine leiomyoma cells 
progesterone may down regulate the expression of ERa phospho-Ser 118 [32]. 
p44/42 MAPK (Mitogen-activated protein kinase) Pathway 
p44/42 MAPK can also be denoted as ERK 1 and 2 (extracellular signal-regulated 
kinases) and are enzymes that phosphorylate proteins that are activated by protein kinase 
cascades that contain at least two upstream kinases [17, 59]. ERK1 and 2 have a 
molecular weight of 44 and 42 kD respectively, and consist of two domains the kinase 
and common docking domain. The p44/42 MAPK pathway is composed of a set of three 
evolutionarily conserved, sequentially acting kinases (contained in all MAPK pathways): 
1) a MAPK (i.e., p44/42): 2) a MAPK kinase (MAPKK - i.e.MEKl & 2): and 3) a 
MAPKK kinase (MAPKKK - i.e., A-Raf, B-Raf, Raf-1 and c-Mos). The MAPKKKs, 
which are serine/threonine kinases are activated by interaction with a small GTP-binding 
protein in response to growth factors and cytokines. MAPKKK activation leads to the 
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phosphorylation of MAPKK, which then stimulates MAPK activity through dual 
phosphorylation on threonine and tyrosine residues. Activated MAPK then 
phosphorylates target substrates (i.e., ER) on serine or threonine residues followed by 
proline residues [59]. Activated ERK 1 and 2 are highly expressed in uterine leiomyoma 
cells. Chegini et al, [14, 27] have demonstrated that activated ERK 1 and 2 are expressed 
more in leiomyoma cells compared to normal myometrial cells and studies in our 
laboratory have shown that activated p44/42 is expressed more in leiomyoma tissue than 
normal myometrial tissue [14, 77]. In breast cancer cells activated p44/42 MAPK has 
been shown to phosphorylate ERa at serine 118 in the presence or absence of E2 [11, 15, 
24]. In a study using human uterine leiomyoma cells, treatment with E2 resulted in the 
secretion of platelet derived growth factor (PDGF) and activation of the MAPK pathway 
[3]. These data demonstrate that in human uterine leiomyoma cells p44/42 MAPK may 
phosphorylate ERa at Ser 118. 
Selective Estrogen Receptor Modulators (SERMs) 
SERMs are nonsteroidal therapeutic agents that bind to the estrogen receptor and 
elicit tissue-specific estrogen agonist and antagonist effects [20]. SERMs have been 
shown to be effective in breast cancer, and preclinical and clinical data suggest that these 
hormonal modulators may also be beneficial for the treatment of uterine leiomyomas. 
Tamoxifen, the most widely used SERM, antagonizes the action of estrogen in the breast 
but acts as an estrogen agonist in the bone, the cardiovascular system, and uterine 
endometrium. The agonistic effects of tamoxifen on the uterus, bone and cardiovascular 
tissue has led to the design of newer SERMs such as raloxifene [20, 52]. Raloxifene is a 
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benzothiophene that has a mixed ER agonist-antagonist effect like tamoxifen. However, 
raloxifene does not have agonistic effects on the endometrium, which makes it a likely 
potential candidate to treat fibroids [20]. Raloxifene was found to significantly reduce 
leiomyoma size in post-menopausal women without affecting the endometrium. The 
results of the therapeutic efficacy of raloxifene in premenopausal women remain 
inconsistent. Palomba et ah reported that raloxifene had no significant effect on 
leiomyoma size in premenopausal women, whereas Jirecek et ah demonstrated that 
treatment with raloxifene inhibited leiomyoma growth in premenopausal women [35, 53]. 
Little information is available regarding the specific mechanisms by which raloxifene can 
cause shrinkage. Also, there are no in vitro studies that have evaluated the effects of 
raloxifene on human uterine leiomyoma cells. Treatment of human uterine leiomyoma 
cells with raloxifene in this proposed study will elucidate some of the mechanisms 
involved in raloxifene's effect on fibroid growth. 
Selective Progesterone Receptor Modulators (SPRMs) 
SPRMs are a class of PR ligands that exerts clinically relevant tissue-selective 
progesterone receptor agonist, antagonist, or partial (mixed) agonist/antagonist effects on 
various progesterone target tissues [18, 52]. Two examples of SPRMs are RU486 
(mifepristone), which behaves as a pure progesterone receptor antagonist, whereas J867 
(asoprisnil) behaves as a mixed agonist/antagonist [18]. Treatment of premenopausal 
women with RU486 resulted in a reduction of leiomyoma size, but was associated with 
adverse effects such as hot flashes, mild elevations of hepatic enzymes, and endometrial 
hyperplasia [52]. These data on the therapeutic efficacy of RU486 were not based on a 
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placebo-controlled based study. In a placebo-controlled study using asoprisnil, 
leiomyoma volume was reduced and the duration and intensity of uterine bleeding was 
suppressed [52]. The most frequently reported adverse events were headache and 
abdominal pain. These reported data suggest that asoprisnil, because of its partial 
agonistic effect, would be a suitable SPRM candidate to use in this proposed study to 
elucidate the mechanisms involved in how asoprisnil affects fibroid growth. 
The molecular mechanisms involved in the interaction between hormones and 
growth factor pathways, and how this interaction plays a role in fibroid development and 
growth is not full understood. Therefore, we hypothesized that ERa is phosphorylated 
at serine 118 by phospho-p44/42 MAPK and this phosphorylation is influenced by 
the levels of £2 and P4 in human uterine leiomyomas. 
To test this hypothesis, cultured human uterine leiomyoma (UtLM) and smooth 
muscle cells ([UtSMC] - for comparative purposes) and uterine leiomyoma and patient-
matched myometrial tissues were used in in vitro and in vivo experiments, respectively. 
The UtSMC and UtLM cells are good in vitro models because their biological 
characteristics are similar to those of human normal myometrium and uterine leiomyoma 
tissue, respectively. Also, they are readily available, and are easily manipulated. Using 
these model cell systems, the following objectives will be addressed as listed below: 
Experimental Objectives 
Objective 1: Determine the differential expression of ERa-phospho-Serll8 and 
phospho-p44/42 MAPK in human uterine leiomyoma and myometrial tissue from 
women in the proliferative or secretory phase of the menstrual cycle. This was 
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performed using western blotting and immunohistochemistry utilizing antibodies that are 
specific for ERa-phospho-Serl 18 and phospho-p44/42 MAPK. Staining of tissues 
samples were assessed and assigned a score using a semiquantitative numeric quickscore 
method. Tissue studies were conducted to co-localize and show the association between 
ERa-phospho-Serl 18 and phospho-p44/42 MAPK in human uterine myometrial and 
leiomyoma tissues using immunofluorescence and immunoprecipitation. Statistical 
analysis of staining was used to determine if there are any significant differences in the 
protein expression of ERa-phospho-Serl 18 and phospho-p44/42 MAPK between tumors 
from women in the proliferative versus secretory phase of the menstrual cycle, and also 
between small versus large tumors. 
Objective 2: In vitro studies were done to determine the effects of E2 and P4 on ERa-
phospho-Serl 18 protein expression and to assess the role of phospho-p44/42 MAPK 
on ERa-phospho-Serl 18 protein expression. In order to inhibit phospho-p44/42 
MAPK, UtLM and UtSMC cells were pretreated with the MAPK inhibitor PD98059. 
The cells were then treated with excess E2 and P4 and E2 and P4 mimicking the 
physiological hormone levels from the proliferative and secretory phases of the menstrual 
cycle. The protein expression, co-localization and association of ERa-phospho-Serl 18 
and phosphop44/42 MAPK were measured using western blotting, immunoflourescence 
and immunoprecipitation, respectively. 
Objective 3: To determine if raloxifene and asoprisnil can regulate phosphorylation 
of ERa at serine 118 by phospho-p44/42 MAPK in human uterine leiomyoma and 
myometrial cells. UtLM and UtSMC cells were treated with raloxifene and asoprisnil 
separately and in combination with their natural ligands (E2 and P4) and then cell 
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proliferation was measured using a MTS assay. The expression of ERa-phospho-Serl 18 
and phospho-p44/42 MAPK was also measured using immunoblotting. 
Significance 
The proposed in vivo and in vitro studies will elucidate the mechanisms involved 
in how the estrogen and progesterone hormone pathways communicate and interact with 
each other, and with growth factor signaling pathways. A better understanding of the 
actions of SERMs and SPRMs on leiomyoma growth will contribute to the effective and 
safe use of these compounds in the treatment of clinical cases of fibroids. Understanding 
the interaction of these pathways and how they regulate uterine leiomyoma growth will 
help develop noninvasive therapeutic strategies for treatment of these tumors. 
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CHAPTER II 
MATERIALS AND METHODS 
Patients 
Uterine leiomyomas (n=26) and unaffected patient-matched myometrial tissue 
(n=16) samples were taken from sixteen premenopausal women (6 for western blot 
analysis x 1 tumor each and 10 for immunohistochemistry x 2 tumors each) who 
underwent hysterectomy for symptomatic fibroids. The women had not taken hormonal 
medication at least 3 months prior to surgery. Informed consent was obtained, and the 
Institutional Review Board (IRB) of the NIEHS NIH approved the study. All uterine 
leiomyoma and unaffected myometrial samples were confirmed by histological 
evaluation. The menstrual cycle phases were determined as either proliferative or 
secretory based on endometrial histology (case 11) or menstrual cycle history (cases 1-10 
and 12-16) for each patient (Table 1). All patients had multiple fibroids that were typical 
in histomorphology and located in the intramural (60%), subserosal (25%) or submucosal 
(15%) regions of the myometrium. Tumor sizes were classified as <2cm (n=10) or >2cm 
(n=10) (Table 1), and the age of the patients ranged from 41 to 47 years with a mean age 
of 43.5 years. 
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Table 1 Tumor Size and Menstrual Cycle Phase of Premenopausal Women with Fibroids 
Case# Menstrual Cycle Phase Tumor ID Tumor Size (cm) 
proliferative 
proliferative 
proliferative 
proliferative 
proliferative 
secretory 
secretory 
secretory 
secretory 
secretory 
proliferative 
proliferative 
proliferative 
secretory 
secretory 
secretory 
la 
lb 
2a 
2b 
3a 
3b 
4a 
4b 
5a 
5b 
6a 
6b 
7a 
7b 
8a 
8b 
9a 
9b 
10a 
10b 
11a 
12a 
13a 
14a 
15a 
16a 
<2 
>2 
<2 
>2 
<2 
>2 
<2 
>2 
<2 
>2 
<2 
>2 
<2 
>2 
<2 
>2 
<2 
>2 
<2 
>2 
>2 
>2 
>2 
>2 
>2 
>2 
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Cell Culture 
Human uterine leiomyoma (UtLM) cells (GM10964; Coriell Institute for Medical 
Research, Camden, NJ, USA) and uterine smooth muscle cells (UtSMC) (Clonetics 
Corporation San Diego, CA, USA) were used for the experiments between passages 11-
13 and were kept in a standard tissue culture incubator at 37°C, 95% humidity and 5% 
CO2. Both cell lines were cultured similarly as previously reported [26]. Briefly, the 
UtSMC cells were cultured using a Smooth Muscle Cell Growth Media System (SmGM-
2 Bulletkit®: Clonetics) and the UtLM cells were grown in GM media containing 
Minimun Essential Medium (MEM; Gibco Life technologies, Grand Island, NY, USA), IX 
vitamins, IX non-essential amino acids, IX essential amino acids, 2X L-glutamine 
(Gibco Technologies) and 20% Fetal Bovine Serum (FBS; Sigma, St. Louis, MO, USA). 
Twenty-four hours prior to the treatment of both cell lines, the media were changed to 
Dulbecco's modified Eagle's medium/nutrient mixture F-12 Ham (DMEM/F-12) 
(Hyclone Laboratories, Logan, UT, USA) phenol red-free with 10% charcoal dextran 
treated FBS (Sigma-Aldrich). 
Western Blotting 
Tissue 
Western blotting was performed to detect ERa-phospho-Serl 18 expression in the 
leiomyoma and patient-matched myometrial tissue lysates, which were taken from 6 
women in the proliferative (3) and secretory (3) phases of the menstrual cycle. Aliquots 
of 30[xg of tissue lysate were electrophoresed on a 4-12% Bis-Tris Gel (Invitrogen, 
Carlsbad, CA, USA) under reducing conditions as previously described [64]. The 
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proteins were electrotransferred onto 0.45 um polyvinylidene fluoride (PVDF) 
membranes (Immobilon-P, Millipore, Bedford, MA, USA). Blots were incubated with a 
mouse monoclonal antibody (Cell Signaling Technology Inc., Danvers, MA, USA) 
against ERa-phospho-Serl 18 diluted at 1:500. Antibody binding was detected with 
horseradish peroxidase-conjugated anti-mouse (Amersham Biosciences, Arlington 
Hights, IL, USA) diluted at 1:2000. Antigen-antibody complexes were detected with the 
ECL western blot detection system (Amersham Biosciences). A densitometer (Fluor 
Chem™8900, Alpha Innotech, San Landro, CA, USA) was used for quantitation of ERa-
phospho-Serl 18 band densities. 
Cells 
In specific aims 2, UtLM and UtSMC cells were pre-treated with PD98059 
(30uM) for 3 hours at 37°C, 95% humidity and 5% CO2 and then treated with excess E2 
(lOnM) or P4 (lOOnM) (Sigma-Aldrich) and with E2 and P4 at concentrations mimicking 
the physiological levels in the proliferative (l.lnM E2 and 2.23nM P4) and secretory 
(0.48nM E2 and 64nM P4) phases of the menstrual cycle for 5 min at 37°C, 95% humidity 
and 5% CO2. The control groups were treated with 0.07% ethanol and 1.16% DMSO. In 
specific aims 3, UtLM and UtSMC cells were treated with raloxifene (InM) and 
Asoprisnil (lOOnM) (Both compounds were a gift from Dr. Donald McDonnell, Duke 
University Medical Center, Durham, NC, USA) in the presence and absence of E2 
(lOnM) or P4 (lOOnM), (Treatment groups: E2, Ral, E2 + Ral, P4, Aso and P4 + Aso) 
respectively and in combination with each other (Treatment groups: Ral & Aso) for 30 
min at 37°C, 95% humidity and 5% CO2. Protein lysates were obtained with a 
radioimmunoprecipitation assay (RIPA) buffer, and protein concentrations were 
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determined by bicinchoninic acid assay (BCA) protein assay (Pierce Biotechnology, 
Rockford, IL, USA). Aliquots of 30jxg of cell protein lysate were electrophoresed on a 4-
12% Bis-Tris Gel under reducing conditions as previously described [64]. Western 
blotting was performed exactly like the procedure described above in the tissue 
immunoblotting section. 
Immunohistochemistry 
ERa-phospho-Serl 18, ERa andphospho-p44/42 MAPK Expression: 
Uterine leiomyoma (20) and myometrial (10) tissue samples were fixed overnight 
in 10% neutral buffered formalin. Tissues were then processed through a graded series of 
alcohols, embedded in paraffin, sectioned at 6um and mounted onto charged glass slides 
(ProbeOn Plus, Fisher Scientific, Pittsburgh, PA, USA). Tissues were deparaffinized and 
endogenous peroxidase activation was blocked using 3% H2O2 for 15 min at room 
temperature. Antigen retrieval was performed by microwaving for 10 min (ERa & ERa-
phospho-Serl 18 staining) or by incubation for 20 min in a decloaker (for phospho-p44/42 
MAPK staining). Tissues were blocked using normal horse or goat serum at room 
temperature for 1 h. The tissues used for ERa and ERa-phospho-Serl 18 was 
additionally blocked using an Avidin/Biotin Blocking Kit (Vector Laboratories, 
Burlingame, CA, USA). Tissues were incubated with phospho-estrogen receptor a 
(Serl 18) monoclonal antibody (1:30 dilution), estrogen receptor monoclonal antibody 
(1:25 dilution; Immunotech Beckman Coulter Inc., Fullerton, CA, USA) or phospho-
p44/42 MAPK polyclonal rabbit IgG (1:50 dilution; Cell Signaling Technology Inc.) 
overnight at 4°C. Negative controls consisted of normal mouse or rabbit serum at a 
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concentration the same as the respective primary antibody. The tissues were incubated in 
the secondary antibody (horse anti-mouse or goat anti-rabbit) (Elite Vectastain ABC Kit, 
Vector Laboratories, Burlingame, CA, USA) for 30 min at room temperature. 
Immunoreactive complexes were detected by avidin-biotin affinity system (Elite 
Vectastain ABC Kit, Vector Laboratories, Burlingame, CA, USA) and visualized using 
3,3'- diaminobenzidine (DAB) tetrahydrachloride substrate chromogen system (Dako 
Cytometry Inc., Carpinteria, CA, USA). Tissues were counterstained with Mayer's 
hematoxylin (Poly Scientific, Bay Shore, NY, USA), dehydrated, coverslipped and 
observed by light microscopy. 
A semi-quantitative numerical score incorporating overall percent of positive 
immunohistochemical staining and intensity of immunostaining was determined for 
assessing ERa-phospho-Serl 18, ERa and phospho-p44/42 MAPK protein expression in 
leiomyoma and myometrial tissue samples using a multiplicative quickscore method 
described by Detre et al. [25] as shown in Table 2. Briefly, a number generated for the 
percent of tissue showing positive immunohistochemical staining (0-4%=l; 5-19%=2; 
20-39%=3; 40-59%=4; 60-79%=5; 80-100%=6) was multiplied by a number generated 
for intensity of staining (negative=0, weak=l, interrnediate=2, or intense=3) for each 
tissue. Slides were evaluated blindly with a light microscope and a 20X objective. 
Quickscores were assigned independently by two scorers and then averaged to obtain a 
mean quickscore. Sections were scanned at 40X using an Aperio ScanScopeXT model 
(Aperio Technologies, Vista, CA, USA) 
23 
Table 2 Quickscore Calculations 
Quickscore 
% Of Staining X Intensity Of Staining 
(1 to 6) (0 to 3) 
1 
2 
3 
4 
5 
6 
0-4% 
5-19% 
20-39% 
40-59% 
60-79% 
80-100% 
0 
1 
2 
3 
negative 
weak 
intermediate 
strong 
Specificity of ERa-phospho-Ser 118 Antibody: 
The immunohistochemical procedures were done similarly as described above for 
ERa-phospho-Ser 118 staining in myometrial and leiomyoma tissue. Prior to overnight 
incubation of myometrial and leiomyoma tissue with phospho-estrogen receptor a 
(Serl 18) monoclonal antibody (Cell Signaling Technology) at a 1:30 dilution, the 
antibody was incubated with a blocking peptide (Cell Signaling Technology) for ERa-
phospho-Serl 18 at a volume twice that of the antibody for 1 hour at room temperature 
with gentle shaking. The blocking peptide for ERa-phospho-Ser 118 is a fourteen amino 
acid peptide that corresponds to the epitope that the antibody binds to preventing the 
antibody from binding to ERa-phospho-Ser 118 protein (Fig. 2). 
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Myometrium Leiomyoma 
Fig. 2 ERa-phospho-Serl 18 immunoexpression in myometrial and leiomyoma tissues in the presence and 
absence of a blocking peptide. ERa-phospho-Serl 18 is expressed the nuclei of myometrial (a and c) and 
leiomyoma (b and d) tissue samples in the absence of the blocking peptide (original magnification, X40). 
Proliferating Cell Nuclear Antigen (PCNA) Labeling: 
For PCNA staining, the deparaffinization and rehydration were done similarly to 
the immunohistochemical procedures described above. After inactivation of endogenous 
peroxidases, antigen retrieval was performed by microwaving the samples for 10 min in 
dH20. Samples were blocked using 0.5% milk for 20 min and then a primary antibody, 
monoclonal mouse anti-PCNA IgM (1:500 dilution; Chemicon Inc, Temecula, CA, USA) 
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was placed on the tissues for 1 h at room temperature. After rinsing, the tissues were 
incubated with a secondary antibody (Biotin-SP-conjugated AffiniPure Goat anti-mouse 
IgM, [i chain specific; Jackson Immunoresearch Inc., West Grove, PA, USA) for 30 min 
at room temperature. Tissues were labeled with supersensitive conjugated streptavidin 
peroxidase (BioGenex, San Ramon, CA, USA). Immunoreactive complexes were 
visualized and tissues were counterstained and coverslipped using the procedures 
mentioned in the previous section. 
The percentage of PCNA labeling in the tissue samples was later determined 
using a light microscope, 40X objective and an ocular grid. Approximately 8-12 high 
power fields per tissue section were counted to reach a total cell count of 1000 cells in 
uterine leiomyoma and myometrial tissues. Nuclei that stained intensely brown were 
counted as positive. Percent PCNA labeling was determined by the number of cells 
having positively stained nuclei divided by 1000 cells (labeled and unlabeled) and 
multiplied by 100. A mean percent PCNA labeling was determined by averaging the 
numbers from the independent scorers. 
Immunoflourescence 
Tissue 
Frozen samples of uterine leiomyoma and patient-matched myometrial tissues 
were sectioned at 5um, thawed for 15 min at room temperature and fixed in 4% 
paraformaldehyde at 4°C for 10 min followed by -20°C methanol for 20 min. The 
sections were then blocked for 1 h in 5% milk, 1% BSA, and 1.5% normal goat serum 
(Vectastain Kit) in IX automation buffer. Tissues were incubated in primary antibodies 
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for both mouse monoclonal ERa-phospho-Serl 18 and polyclonal rabbit phospho-p44/42 
MAPK together overnight (4°C) at dilutions as stated above in the immunohistochemistry 
section. The sections were then incubated with Alexa Fluor 488 goat anti-mouse IgG 
(green fluorescence) and Alexa Fluor 594 goat anti-rabbit IgG (red fluorescence) 
(Molecular Probes, Carlsbad, CA, USA) for 45 min at room temperature in the dark. 
Tissues were counterstained using 4', 6-diamidino-2-phenylindole (DAPI; Molecular 
Probes, Carlsbad, CA USA) in the dark for 30 min at room temperature. Sections were 
coverslipped with aqueous anti-fade fluorescent mounting medium (Vector Laboratories, 
Burlingame, CA, USA). The tissue sections were observed with a laser scanning 
confocal microscope (LSM 510 UV mounted on Axiovert 100M microscope, Carl Zeiss, 
Inc.) and analyzed using LSM Image Examiner v3.2 software. 
Cells 
Thirty thousand cultured human uterine leiomyoma (UtLM) and uterine smooth 
muscle cells (UtSMC) were grown to 80% confluency on 35mm glass bottom microwell 
dishes and treated with E2 and P4 (Sigma-Aldrich) at concentrations mimicking the 
physiological levels in the proliferative (0.48nM E2 and 2.23nM P4) and secretory (l.lnM 
E2 and 64nM P4) phases of the menstrual cycle for 5 min at 37°C, 95% humidity and 5% 
CO2. After the cells were rinsed with Phosphate buffer saline (PBS) they were fixed in 
4% paraformaldehyde on ice for 15 minutes. After permeabilizing the cells using 0.1% 
triton X-100 in PBS, the cells were block for two hours with 5% BSA + 0.1% gelatin 
(Sigma-Aldrich) in PBS on ice. Cells were incubated in primary antibodies for both 
ERa-phospho-Serl 18(1:300) and phospho-p44/42 MAPK (1:200) together overnight at 
4°C. The cells were then incubated with Alexa Fluor 488 (1:3000) goat anti-mouse IgG 
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(green fluorescence) and Alexa Fluor 594 (1:2000) goat anti-rabbit IgG (red 
fluorescence) (Molecular Probes, Carlsbad, CA, USA) for 1 hour on ice in the dark. 
Cells were counterstained using DAPI (4', 6-diamidino-2-phenylindole, Molecular 
Probes, Carlsbad, CA USA) in the dark for 30 minutes at room temperature. After the 
cells were rinsed with PBS, they were observed by a laser scanning confocal microscope 
and analyzed using LSM image Examiner v3.2 software. 
Immunoprecipitation 
Tissue 
To assess the association of ERa-phospho-Ser 118 and phospho-p44/42 MAPK in 
myometrial and leiomyoma tissues, phospho-p44/42 MAPK was immunoprecipitated arid 
immunoblotted for ERa-phospho-Ser 118 and phospho-p44/42 MAPK (as a control). 
Aliquots of 500ug of leiomyoma and myometrial tissue lysates were cleared by adding 
50uL of Protein A-Sepharose beads (Zymed Laboratories Inc, San Francisco, CA, USA) 
and incubated for 30 min at 4°C with gentle rotation. The protein lysates were 
immunoprecipitated with 5ug of phospho-p44/42 MAPK polyclonal rabbit antibody (Cell 
Signal Technology) overnight at 4°C with gentle rotation. 50uL of 50% Protein A-
Sepharose beads were added to each tube, the mixtures were incubated overnight at 4°C, 
and the immune complexes were collected by centrifugation. The beads were washed 
with RIPA buffer (10 mL of 50 mM Tris HCL pH 7.4 w/150 mM NaCL, ImM EGTA, 
ImM NaF, and 1% triton X 100,250uL of 10% sodium deoxycholate, 50uL of 200 mM 
activated sodium vanadate, 50uL of 10 mM sodium molybdate, 20uL of aprotinin and 
leupeptin and 20jxL of 2jxg/ml of A-PMSF) and the supernatant was discarded. The 
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sepharose beads were resuspended in 30jxL of Laemmli sample buffer (Bio-Rad 
Laboratories, Hercules, CA, USA) and then centrifuged. Amounts of \5\iL of the 
supernatant were used for immunoblotting as previously described (mouse monoclonal 
ERa-phospho-Serl 18 antibody at 1:500 dilution and rabbit polyclonal phospho-p44/42 
MAP Kinase antibody at 1:1000 dilution (Cell Signaling Technology). Antibody binding 
was detected with horseradish peroxidase-conjugated anti-mouse and anti-rabbit 
(Amersham Biosciences) diluted at 1:2000. Antigen-antibody complexes were detected 
with an ECL western blot detection system (Amersham Biosciences). 
Cells 
UtSMC and UtLM cells were treated with E2 and P4 (Sigma-Aldrich) at 
concentrations representing the physiological levels of the proliferative (0.48nM E2 and 
2.23nM P4) and secretory (l.lnM E2 and 64nM P4) phases of the menstrual cycle for 5 
min at 37°C, 95% humidity and 5% CO2. 500ug of cell lysates from each treatment were 
used for immunoprecipitation following the procedure stated above in the tissue section. 
Cell Proliferation Assay 
Cell proliferation was determined using a colorimetric assay (CellTiter 96® 
AQueous One Solution Cell Proliferation assay, Promega Corporation, Madison, WI, 
USA). UtLM and UtSMC cells were seeded into 96-well plates at 4 x 103 cells per well, 
and cultured in phenol red-free DMEM/F-12 containing 10% charcoal-stripped FBS for 
24h. Cells were treated with raloxifene (InM) and Asoprisnil (lOOnM) in the presence 
and absence of E2 (lOnM) and P4 (lOOnM), (Treatment groups: E2, Ral, E2 + Ral, P4, Aso 
and P4 + Aso) respectively and in combination (Treatment groups: Ral & Aso) with each 
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other. Cell proliferation was determined according to the manufacturer's protocol at 72 
hrs. Spectrophotometric analysis was measured by using a microplate reader (Molecular 
Devices Corporation, Sunnyvale, CA, USA). The absorbance is directly proportional to 
the number of living cells present. The experiments were repeated three times, each with 
at least four replicates. 
Statistics 
Statistical comparisons were performed for mean of quickscores and intensities 
for western blot bands of uterine leiomyoma and patient-matched myometrial samples. 
Significant differences were determined using Wilcoxon signed ranks tests (p< 0.05) and 
Mann-Whitney tests (p< 0.05). 
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CHAPTER III 
RESULTS 
ERa-phospho-Serll8 Expression by Western Blot and Densitometry 
Western blot analysis showed significantly increased expression of ERa-
phospho-Serl 18 in uterine leiomyomas compared to myometrial samples from the 
proliferative phase (Fig 3a and 3b). The overall mean expression levels of ERa-
phospho-Serl 18 were slightly higher in uterine leiomyomas from the secretory phase 
compared to myometrial samples although overall this difference was not significant (Fig 
3a and 3b). Also, ERa-phospho-Serl 18 expression was higher in both tumors and 
myometrial samples from the proliferative phase compared to those from the secretory 
phase (Fig. 3a and 3b). 
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Fig. 3 Immunoblot of ERa-phospho-Serl 18 expression in myometrial and leiomyoma tissue lysates. Uterine 
leiomyoma (L) and patient-matched myometrial (M) were taken from women (n=6) in the proliferative or secretory 
phase of the menstrual cycle. HPRT was used as a loading control, (a) ERa-phospho-Serl 18 is expressed in 
leiomyoma and myometrial tissue, (b) The bar graph represents the mean + S.E. (standard error) intensity of 
western blot bands for ERa phospho-Serl 18 protein. Increased expression of ERa-phospho-Serl 18 was observed 
in the leiomyomas compared to the myometrial tissue samples from the proliferative phase of the menstrual cycle. " 
* " represents a significant difference versus myometrial samples (p s 0.05; n=6). 
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ERa-phospho-Serll8 and ERa Expression by Immunohistochemistry 
Proliferative Phase 
Immunohistochemistry confirmed that leiomyoma samples from the proliferative 
phase had increased protein expression of ERa-phospho-Serl 18 compared to matched-
myometrial tissue (Fig. 4). ERa-phospho-Serl 18 was expressed in the nuclei of 
myometrial and leiomyoma cells (Fig. 4a and 4b). Also in this phase, ERa expression 
was increased in the tumors compared to myometrial tissue, and was expressed 
predominantly in the nuclei of myometrial and leiomyoma cells with minimal staining in 
the cytoplasm (Fig. 4c and 4d). Scores of immunostaining intensity showed significant 
differences in ERa-phospho-Serl 18 expression in myometrial versus leiomyoma samples 
with mean quickscores of 2.4 ±1.0 and 8.0 ± 1.3, respectively (Fig. 4e). Mean 
quickscores for ERa immunoexpression in myometrial and leiomyoma samples were 7.7 
± 2.0 and 16.6 ± 0.6, respectively (Fig. 3e). 
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Fig. 4 Immunoexpression of ERa-phospho-Serl 18 and ERa in myometrial and leiomyoma tissues from 
the proliferative phase, (a and b) ERa-phospho-Serl 18 expression in myometrium (a) and leiomyoma (b) 
tissue samples, (c and d) ERa expression in myometrium (c) and leiomyoma (d) tissue samples. Arrows 
show positively stained nuclei of cells, (e) The bar graph represents the mean + S.E. of quickscore values 
for ERa-phospho-Serl 18 and ERa in myometrial tissue and tumors. " * " represents a significant 
difference versus myometrial samples (p s 0.05; n=10 for myometrial samples and n=20 for leiomyoma 
samples; original magnification, X40). 
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Secretory Phase 
Both leiomyoma and myometrial tissues from the secretory phase showed 
expression of ERa-phospho-Serl 18 (Fig. 5); however, ERa-phospho-Serl 18 expression 
was significantly lower in the myometrium (0.1 ±0.1) compared to leiomyoma (3.6 ± 
0.5) tissues (Fig. 5a and 5b). ERa expression was also significantly lower in myometrial 
tissue compared to leiomyomas (myometrium =6.4 ± 1.3; leiomyoma=12.7 ± 2.2) (Fig. 
5e). 
When ERa-phospho-Serl 18 expression in leiomyomas from the secretory phase 
was compared to those from the proliferative phase, we found that ERa-phospho-Serl 18 
was expressed at significantly higher levels in the leiomyomas from the proliferative (8.0 
± 1.3) versus secretory (3.6 ± 0.5) phase (Fig. 4e and 5e). Also, no significant differences 
in ERa and ERa-phospho-Serl 18 immunoexpression were observed between small 
leiomyomas (<2cm) and large leiomyomas (> 2cm) when tumors from both phases were 
combined or evaluated independently by phase (data not shown). 
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Fig. 5 Immunoexpression of ERa-phospho-Serl 18 and ERa in myometrial and leiomyoma tissues from 
the secretory phase, (a and b) ERa-phospho-Serl 18 expression in myometrium (a) and leiomyoma (b) 
tissue, (c and d) ERa expression in myometrium (c) and leiomyoma (d) tissue samples. Arrows show 
positively stained nuclei of cells, (e) The bar graph represents the mean + S.E. of quickscore values for 
ERa-phospho-Serl 18 and ERa in myometrial tissue and tumors. " * " represents a significant difference 
versus myometrial samples (p s 0.05; n=10 for myometrial samples and n=20 for leiomyoma samples; 
original magnification, X40). 
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Expression of phospho-p44/42 MAPK by Immunohistochemistry 
Due to increased expression of ERa-phospho-Serl 18 in leiomyomas, we 
evaluated phosphorylated p44/42 MAPK (phospho-p44/42 MAPK) expression in 
leiomyomas and myometrial tissue samples from the same ten patients used for the ERa 
and ERa-phospho-Serl 18 studies (Fig. 6). Overall, phospho-p44/42 MAPK was 
expressed in the nuclei of myometrial and leiomyoma cells (Fig. 6a and 6b). In the 
proliferative phase, phospho-p44/42 MAPK was expressed at significantly higher levels 
in leiomyomas (9.2 + 2.4) compared to myometrial (4.8 + 2.3) tissues (Fig. 6c). No 
significant difference was observed in the expression of phospho-p44/42 MAPK in 
myometrial (4.4 +_1.4) and leiomyoma (4.4 + 0.9) samples from women in the secretory 
phase. Although phospho-p44/42 MAPK was higher in leiomyomas from the 
proliferative phase, when mean expression data were compared between the two phases, 
there was no statistical difference in expression. Interestingly, a significant difference (p 
< 0.05) in phospho-p44/42 MAPK immunoexpression was observed between myometrial 
samples and small leiomyomas (<2 cm) from the proliferative phase (4.8 + 2.3 and 11 + 
3.1, respectively). 
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Fig. 6 Immunoexpression of phospho-p44/42 MAPK in myometrial and leiomyoma tissues from the 
proliferative and secretory phases. Phospho-p44/42 MAPK expression was expressed in the nuclei of 
myometrial (a and b) and tumor (c and d) smooth muscle cells, although it was significantly increased in 
tumors from the proliferative phase, (c) The bar graph represents the mean + S.E. of quickscore values for 
phospho-p44/42 MAPK in myometrial tissue and leiomyomas from the proliferative and secretory phases 
of the menstrual cycle. " * " represents a significant difference versus myometrial samples in the 
proliferative phase (p s 0.05; n=10 for myometrial samples and n=20 for leiomyoma samples; original 
magnification, X40). 
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Colocalization of ERa-phospho-Serll8 and phospho-p44/42 MAPK in Myometrial 
and Leiomyoma Tissues 
To determine if significantly increased levels of ERa-phospho-Serl 18 and 
phospho-p44/42 MAPK observed in the tumors from the proliferative phase were 
colocalized, we conducted immunoflourescence and confocal microscopy studies to 
evaluate the localization of ERa-phospho-Serl 18 (Fig. 7a and b) and phospho-p44/42 
MAPK (Fig. 7c and d) in tumor and myometrial tissues from the proliferative phase. 
Both ERa-phospho-Serl 18 and phospho-p44/42 MAPK were present in the nuclei of 
myometrial and leiomyoma tissue samples (Fig. 7a, b, c, d). Colocalization was more 
apparent in the nuclei of leiomyoma cells compared to myometrial cells in tissue samples 
(Fig. 7e and f). 
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Fig. 7 Co localization of ERa-phospho-Serl 18 and phospho-p44/42 MAPK in myometrial and leiomyoma 
tissues from the proliferative phase. Arrows show nuclei in the inset (top right corner) that are positively 
stained for ERa-phospho-Serl 18 (green fluorescence; a and b), phospho-p44/42 MAPK (red fluorescence; 
c and d), and both ERa-phospho-Serl 18 and phospho-p44/42 MAPK (white/yellow fluorescence; e and f) 
in myometrial (a, c, and e) and leiomyoma (b, d and f) tissues. DAPI was used to stain the nuclei (blue 
fluorescence; e and f) (original magnification, X40/zoom of 1). 
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Immunoprecipitation of ERa-phospho-Serll8 and phospho-p44/42 MAPK in 
Leiomyoma and Myometrial Tissue 
To show the interaction of ERa-phospho-Serl 18 and phospho-p44/42 MAPK in 
myometrial and leiomyoma tissues from the proliferative phase, phospho-p44/42 MAPK 
was immunoprecipitated from myometrial and leiomyoma tissues, and then 
immunoblotted for ERa-phospho-Serl 18 and phospho-p44/42 MAPK (control) (Fig. 8). 
There was an increased association of ERa-phospho-Serl 18 and phospho-p44/42 MAPK 
in leiomyomas compared to myometrial tissue. 
IP: Phospho-p44/42 MAPK 
Fig. 8 Immunoprecipitation of ERa-phospho-Serl 18 and phospho-p44/42 MAPK from myometrial and 
leiomyoma tissues from the proliferative phase. Phospho-p44/42 MAPK was immunoprecipitated (IP) 
from leiomyoma and myometrial tissue and then immunoblotted (IB) with the anti-ERa-phospho-Serl 18 
(66 kiloDaltons (kD)) and phospho-p44/42 MAPK (44 and 42 kD; control) antibodies. 
Proliferating Cell Nuclear Antigen (PCNA) Labeling 
Based on our findings of increased ERa-phospho-Serl 18 expression in 
leiomyomas and the abundant association and colocalization of phospho-p44/42 MAPK 
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and ERa-phospho-Serl 18 in tumors during the proliferative phase, we conducted PCNA 
labeling studies to assess whether there would be differential expression of this cell 
proliferation marker in tumors versus myometrial samples from the proliferative and 
secretory phases. PCNA was highly expressed in tumors compared to myometrial tissue 
in both the proliferative and secretory phases with more expression in the proliferative 
phase tumors compared to those from the secretory phase (Fig. 9a-9d). We found that the 
mean PCNA labeling indices were significantly higher in tumors versus myometrial 
tissue in both the proliferative and secretory phases of the menstrual cycle (Fig. 9e). 
Also, PCNA labeling in tumors from women in the proliferative phase was significantly 
higher than in tumors from the secretory phase (28.60+ 3.20 and 18.39 + 3.20, 
respectively). No significant differences were observed in the PCNA labeling in small 
leiomyomas (< 2cm) compared to large (> 2 cm) leiomyomas when combined, or 
evaluated independently by phase; although in both phases the mean labeling indices 
were higher in the smaller leiomyomas. 
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Fig. 9 Immunoexpression of Proliferating Cell Nuclear Antigen (PCNA) in myometrial and leiomyoma 
tissues from the proliferative and secretory phases (a-d) (original magnification, X40). (e) Bar graph 
represents the mean + S.E. of percent of cells labeled with PCNA in myometrial (white bar) and leiomyoma 
(black bar) tissues. " * " represents a significant difference versus myometrial tissue and "a" represents 
significance between leiomyomas of the proliferative versus secretory phase of the menstrual cycle (p s 
0.05; n=10 for myometrial samples and n=20 for leiomyoma samples). 
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Expression of ERa-phospho-Serll8 and phospho-p44/42 MAPK after treatment 
with E2, P4, and PD98059 in UtLM and UtSMC cells. 
In order to support the tissue studies which showed that in human uterine 
leiomyomas, phospho-p44/42 MAPK may be the kinase that phosphorylates ERa at 
serine 118, and this phosphorylation may be enhanced during the proliferative (E2 
dominant phase) phase, in vitro studies were done whereby UtLM and UtSMC cells were 
pretreated with the MAPK inhibitor PD98059 in the presence or absence of E2 and P4 
representing the physiological hormone levels of the proliferative and secretory phases of 
the menstrual cycle. The expression levels of ERa-phospho-Serl 18 and phospho-p44/42 
MAPK were evaluated by using western blot analysis (Fig. 10 and 11). ERa-phospho-
Serl 18 and phospho-p44/42 MAPK were differentially expressed in UtLM cells between 
the different treatment groups (Fig. 10a). ERa-phospho-Serl 18 was significantly 
expressed more in the Prol and Sec treatments groups compared to the ethanol VC (VC 
ETOH) (10b). Also, ERa-phospho-Serl 18 expression was significantly more in the Prol 
+ PD and Sec + PD groups compared to both vehicle control groups (VC ETOH and VC 
DMSO) and the PD group (10b). The expression of ERa-phospho-Serl 18 and phospho-
p44/42 MAPK were significantly decreased in the proliferative + PD and secretory + PD 
groups compared to the proliferative and secretory groups without PD, respectively (Fig. 
10b). In the Sec treatment group ERa-phospho-Serl 18 was expressed significantly less 
compared to the Prol treatment group (10b). 
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Fig. 10 Immunoblot analysis of ERa-phospho-Serl 18 and phospho-p44/42 MAPK expression from UtLM 
cell lysate after treatment with proliferative and secretory phase hormones in the presence and absence of 
PD98059. HPRT was used as a loading control. The control groups were treated with 0.07% ethanol (VC 
ETOH) and 1.16% DMSO (VC DMSO). (a) ERa-phospho-Serl 18 and phospho-p44/42 MAPK were 
differentially expressed in UtLM cells between treatment groups, (b) The bar graph represents the mean + 
S.E. (n=3) intensity of western blot bands for ERa-phospho-Serl 18 and phospho-p44/42 MAPK proteins. 
Increased expression of ERa-phospho-Serl 18 and phospho-p44/42 MAPK were observed in the Prol and 
Sec treatment groups compared to the Prol + PD and Sec + PD, respectively, "a" represents statistical 
difference from VC ETOH, "b" is statistically different from VC ETOH, VC DMSO and PD (p s 0.05). " 
* and ** " represents a significant difference versus group without the PD (p s 0.05). "c" = ( p s 0.05). 
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Both ERa-phospho-Serl 18 and phospho-p44/42 MAPK were expressed in 
UtSMC cells after treatment with E2 and P4 mimicking the physiological levels of the 
proliferative and secretory phases of the menstrual cycle (Fig. 1 la). Phospho-p44/42 
MAPK was differentially expressed between treatment groups (Fig. 1 la). There was no 
significant difference in the expression of ERa-phospho-Serl 18 between treatments 
groups although, phospho-p44/42 MAPK expression increased significantly in the 
proliferative and secretory groups compared to the Prol+PD and Sec+PD groups, 
respectively (Fig. lib). 
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Fig. 11 Immunoblot analysis of ERa-phospho-Serl 18 and phospho-p44/42 MAPK expression from 
UtSMC cell lysate after treatment with proliferative and secretory phase hormones in the presence and 
absence of PD98059. HPRT was used as a loading control. The control groups were treated with 0.07% 
ethanol (VC ETOH) and 1.16% DMSO (VC DMSO). (a) ERa-phospho-Serl 18 is expressed and phospho-
p44/42 is differentially expressed in UtSMC cells between treatment groups, (b) The bar graph represents 
the mean + S.E. (n=3) intensity of western blot bands for ERa phospho-Serl 18 and phospho-p44/42 
MAPK proteins. Increased expression of phospho-p44/42 MAPK was observed in the Prol and Sec 
treatment groups compared to the Prol + PD and Sec + PD groups, respectively. " * " represents a 
significant difference versus group without the PD (p s 0.05). 
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To further verify that phospho-p44/42 MAPK phosphorylates ERa at serine 118, 
and is enhanced during E2 dominant phase (proliferative phase), UtLM and UtSMC cells 
were also treated with excess amounts of E2 (lOnM) and P4 (lOOnM) in the presence and 
absence of PD98059 (Fig. 12 and 13). ERa-phospho-Serll8 and phospho-p44/42 
MAPK were differentially expressed in UtLM cells between the different treatment 
groups (Fig. 12a). ERa-phospho-Serl 18 was significantly expressed more in the E2 
treatment group compared to the ethanol VC (VC ETOH) (Fig. 12b). The expression of 
ERa-phospho-Serl 18 significantly decreased in the E2 + PD versus the E2 group. The 
expression of phospho-p44/42 MAPK was significantly decreased in the E2 + PD and P4 
+ PD groups compared to the E2 and P4 groups without PD, respectively (Fig. 12b). 
Also, in the P4 treatment group ERa-phospho-Serl 18 was expressed significantly less 
compared to the E2 treatment group (12b). 
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Fig. 12 Immunoblot analysis of ERa-phospho-Serl 18 and phospho-p44/42 MAPK expression from UtLM 
cell lysate after treatment with excess of E2 and P4 in the presence and absence of PD98059. HPRT was 
used as the loading control. The control groups were treated with 0.07% ethanol (VC ETH) and 1.16% 
DMSO (VC DMSO). (a) ERa-phospho-Serl 18 and phospho-p44/42 MAPK were differentially expressed 
in UtLM cells between treatment groups, (b) The bar graph represents the mean + S.E. (n=3) intensity of 
western blot bands for ERa-phospho-Serl 18 and phospho-p44/42 MAPK proteins. Increased expression 
of ERa-phospho-Serl 18 was observed in the E2 versus E2 + PD treatment group and increased phospho-
p44/42 MAPK expression was observed in the E2 and P4 treatment groups compared to the E2 + PD and P4 
+ PD, respectively, "a" represents statistical difference from VC ETOH, "b" = (p <; 0.05). 
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ERa-phospho-Serl 18 and phospho-p44/42 MAPK were also expressed in 
UtSMC cells after treatment with E2 and P4 (Fig. 13b). Phospho-p44/42 MAPK was 
differentially expressed between treatment groups (Fig. 13b). There was no significant 
difference in the expression of ERa-phospho-Serl 18 between treatments groups 
although, phospho-p44/42 MAPK expression increased significantly in the E2 and P4 
groups compared to the E2+PD and P4+PD groups, respectively (Fig. 13b). 
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Fig. 13 Immunoblot analysis of ERa-phospho-Serl 18 and phospho-p44/42 MAPK expression from 
UtSMC cell lysate after treatment with excess of E2 and P4 in the presence and absence of PD98059. 
HPRT was used as the loading control. The control groups were treated with 0.07% ethanol (VC ETH) and 
1.16% DMSO (VC DMSO). (a) ERa-phospho-Serl 18 is expressed and phospho-p44/42 is differentially 
expressed in UtSMC cells between treatment groups, (b) The bar graph represents the mean + S.E. (n=3) 
intensity of western blot bands for ERa phospho-Serl 18 and phospho-p44/42 MAPK proteins. Increased 
expression of phospho-p44/42 MAPK was observed in the E2 and P4 treatment groups compared to the E2 + 
PD and P4 + PD groups, respectively. " * " represents a significant difference versus group without the PD 
(p =s 0.05). 
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Immunoprecipitation of ERa-phospho-Serll8 and phospho-p44/42 MAPKfrom 
UtSMC and UtLM cells 
To determine if there was an increase in the direct interaction of ERa-phospho-
Serl 18 and phospho-p44/42 MAPK in leiomyoma cells during the proliferative phase. 
Phospho-p44/42 MAPK was immunoprecipitated from UtLM and UtSMC cells after 
being treated with E2 and P4 representing the physiological hormone levels of the 
proliferative and secretory phases of the menstrual cycle and then blotted with ERa-
phospho-Serl 18 and phospho-p44/42 MAPK (control) (Fig. 14). In UtLM cells treated 
with E2 and P4 representing the proliferative phase, there was increased association of 
ERa-phospho-Serl 18 and phospho-p44/42 MAPK compared to UtLM cells treated with 
E2 and P4 representing the secretory phase (Fig. 14a). In UtSMC cells, there was no 
difference in the association of ERa-phospho-Serl 18 and phospho-p44/42 MAPK after 
cells were treated with concentrations of E2 and P4 representing the proliferative or 
secretory phase of the menstrual cycle (Fig. 14b). 
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Fig. 14 Immunoprecipitation of ERa-phospho-Serl 18 and phospho-p44/42 MAPK from UtLM and 
UtSMC cells after treatment with proliferative and secretory phase hormones. Treatment with 0.07% 
ethanol was used as a vehicle control (VC). Phospho-p44/42 MAPK was immunoprecipitated (IP) from (a) 
UtLM and (b) UtSMC cells and then immunoblotted (IB) with anti-ERa-phospho-Serl 18 (66 kiloDaltons 
(kD)) and phospho-p44/42 MAPK (44 and 42 kD; control) antibodies. 
Colocalization of ERa-phospho-Serl 18 and phospho-p44/42 MAPK in UtLM and 
UtSMC Cells 
To verify the increased interaction between ERa-phospho-Serl 18 and phospho-
p44/42 MAPK observed in UtLM cells treated with hormones representing the 
proliferative phase, we conducted immunoflourescence and confocal microscopy studies 
to evaluate the localization of ERa-phospho-Serl 18 and phospho-p44/42 MAPK (Fig. 
53 
15) in uterine leiomyoma and myometrial cells. Both ERa-phospho-Serl 18 and 
phospho-p44/42 MAPK were present in the nuclei of UtLM (Fig. 15a-15d) and UtSMC 
(Fig. 15e-15f) cells. Phospho-p44/42 MAPK was also expressed in the perinulear area of 
UtLM and UtSMC cells. Colocalization was more apparent in the nuclei of leiomyoma 
cells treated with hormones mimicking the proliferative phase (Fig. 15a) compared to the 
secretory phase (Fig. 15b). There was no difference in the co-expression of ERa-
phospho-Serl 18 and phospho-p44/42 MAPK between UtSMC cells treated with the 
proliferative (Fig. 15e) versus the secretory (Fig. 15f) phase hormones. 
UtLM 
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Fig. 15 Colocalization of ERa-phospho-Serl 18 and phospho-p44/42 MAPK in UtLM and UtSMC cells 
after treatment with proliferative and secretory phase hormones. Arrows show nuclei that are positively 
stained for both ERa-phospho-Serl 18 and phospho-p44/42 MAPK (white/yellow fluorescence;) in UtLM 
(a-d) and UtSMC (e-h) cells from the proliferative (a and e) and secretory (b and f) phase. Cells were 
treated with 1.17% ethanol as the vehicle control (c and g). Cells were treated with normal mouse and 
rabbit serum for negative control (d and h). DAPI was used to stain the nuclei (blue fluorescence) (original 
magnification, X40/zoom of 1). 
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Expression of ERa-phospho-Serll8 and phospho-p44/42 MAPK after treatment 
with Raloxifene and Asoprisnil in UtLM and UtSMC cells. 
To determine if the phosphorylation of ERa at Ser 118 by phospho-p44/42 MAPK 
is involved in the mechanisms of action of the clinical compounds raloxifene and 
asoprisnil, ERa-phospho-Serl 18 protein expression was measured after UtLM and 
UtSMC cells were treated with raloxifene and Asoprisnil in the presence or absence of E2 
and P4 (Treatment groups: E2, Ral, E2 + Ral, P4, Aso and P4 + Aso), respectively (Fig. 16 
and 17). In UtLM cells, ERa-phospho-Serl 18 was differentially expressed between 
treatment groups (Fig. 16a). The overall mean expression ERa-phospho-Serl 18 was 
significantly increased in UtLM cells in the E2 and E2 + Ral treatment groups compared 
to the vehicle control (Fig. 16b). Also, the overall mean expression of ERa-phospho-
Serl 18 was significantly lower in the Ral and E2 + Ral treatment groups compared to the 
E2 treatment group (Fig. 16b). Phospho-p44/42 MAPK was highly expressed is UtLM 
cells after treatments, but was not expressed differentially between treatment groups 
(16a). 
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Fig. 16 Immunoblot analysis of ERa-phospho-Serl 18 and phospho-p44/42 MAPK in UtLM cells after 
treatment with raloxifene and asoprisnil in the presence and absence of E2 and P4. HPRT was used as a 
loading control. The control groups were treated with 0.4% ethanol (VC). (a) ERa-phospho-Serl 18 is 
differentially expressed and phospho-p44/42 is expressed in UtLM cells between treatment groups, (b) The 
bar graph represents the mean + S.E. (n=3) intensity of western blot bands for ERa phospho-Serl 18 
protein. Increased expression of ERa phospho-Serl 18 was observed in the E2 and E2 + Ral treatment 
groups compared to VC. Decreased expression of ERa phospho-Serl 18 was observed in the Ral and E2 + 
Ral treatment groups compared to E2 treated group " * " represents a significant difference versus VC (p s 
0.05). " a " represents significant difference versus E2 treated group (p s 0.05). 
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ERa-phospho-Serl 18 protein was expressed in UtSMC cells after raloxifene and 
asoprisnil treatments but was not expressed differentially (Fig. 17). Also, there were no 
changes in the expression phospho-p44/42 MAPK observed between the different 
treatment groups in UtSMC cells (Fig. 17a). 
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Fig. 17 Immunoblot analysis of ERa-phospho-Serl 18 and phospho-p44/42 MAPK in UtSMC cells after 
treatment with raloxifene and asoprisnil in the presence and absence of E2 and P4. HPRT was used as a 
loading control. The control groups were treated with 0.4% ethanol (VC). (a) ERa-phospho-Serl 18 and 
phospho-p44/42 MAPK was not expressed differentially in UtSMC cells between treatment groups, (b) 
The bar graph represents the mean + S.E. (n=3) intensity of western blot bands for ERa phospho-Serl 18 
protein (p s 0.05). 
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Proliferation of UtLM and UtSMC cells after treatment with Raloxifene and 
Asoprisnil in the presence and absence of E2 and P4. 
To determine if Raloxifene and Asoprisnil were able to affect uterine leiomyoma 
growth, UtLM and UtSMC cell proliferation was measured after treatment with 
raloxifene and asoprisnil in the presence and absence of E2 and P4 (Treatment groups: E2, 
Ral, E2 + Ral, P4, Aso and P4 + Aso), respectively (Fig. 18) using a MTS colorimetric 
assay. As shown in Fig. 18a, E2 and E2 + Ral had a stimulatory effect on UtLM cell 
growth compared to VC, although the stimulatory effect of E2 was reduced in UtLM cells 
when treated with Ral and E2 + Ral (Fig. 18a). There was no change in the growth of 
UtSMC cells between the different treatment groups (Fig. 18b). 
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Fig. 18 Proliferation of UtLM and UtSMC cells after treatment with raloxifene and asoprisnil in the 
presence and absence of E2 and P4. The control groups were treated with 0.4% ethanol (VC). All 
experiments were repeated at least three times with four replicates per experiment. Results are presented as 
mean + S.E. (n=3). " * " represents a significant difference versus VC (p s 0.05). " a " represents 
significant difference versus E2 treated group (p s 0.05). 
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CHAPTER IV 
DISCUSSION 
To our knowledge, this is the first study to evaluate ERa-phospho-Serl 18 
expression in human uterine leiomyoma and myometrial tissues and cells. These data 
show that ERa is a phosphoprotein that is phosphorylated at serine 118 residues in 
uterine leiomyomas. Phosphorylation of ERa at serine 118 has been extensively studied 
in breast cancer cells and has been shown to be enhanced in response to estradiol binding 
and through the action of second messenger signaling pathways [42]. Previous in vitro 
and in vivo studies have demonstrated that ERa is phosphorylated at serine 118 in the 
presence or absence of estradiol, and by growth factor peptides and their receptors 
through activation of the MAPK (ERK 1/2) pathway, which can lead to transcription [15, 
24]. ERa from calf uterus is phosphorylated at serine residues in response to estradiol 
[24]. Also, phosphorylation of mouse uterine ERa at serine residues is enhanced in 
response to estrogen [74]. In our study, ERa-phospho-Serl 18 protein levels were highly 
expressed in leiomyoma tissue compared to myometrial tissue samples. Using 
immunohistochemistry, we specifically showed that expression levels of ERa-phospho-
Serl 18 were significantly higher in tumors compared to myometrial samples from 
women in the proliferative phase of the menstrual cycle and to tumors in the secretory 
phase. Although expression was present to a lesser extent in tumors, from the secretory 
phase, it was significantly higher than that of myometrial samples from this phase. These 
results indicate that phosphorylation of ERa at serine 118 may be upregulated in uterine 
leiomyomas from the proliferative phase which, is the estrogen dominant phase. There is 
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evidence suggesting that estradiol can increase the expression of ERa-phospho-Serl 18 in 
breast cancer cells [15]. Estrogen has also been shown to increase uterine leiomyoma 
cell proliferation and progesterone receptor mRNA and protein expression [37]. 
Whereas, progesterone has been shown to have a dual effect on the growth of uterine 
leiomyomas by decreasing and increasing the size of some fibroids in women treated 
with levonorgestrel (a progestin) [76]. Also, in studies comparing estrogen receptor 
protein expression in leiomyomas taken from women in the proliferative and secretory 
phases of the menstrual cycle, the ER protein was expressed at lower levels during the 
secretory phase [7, 39, 78]. 
In this study, we used immunohistochemistry and found nuclear expression of 
phospho-p44/42 MAPK to be significantly increased in leiomyomas compared to 
myometrial tissue in the proliferative phase of the cycle. Chegini et al, have 
demonstrated that phospho-p44/42 MAPK is expressed more in leiomyomas compared to 
myometrial tissue, but this difference was not significant and no menstrual phase data 
was reported in this study. In our study, there was no significant difference in phospho-
p44/42 MAPK expression in tumors in the secretory phase compared to patient-matched 
myometrial samples, and when tumors from both phases of the cycle were combined this 
resulted in a lack of significance of expression of phospho-p44/42 MAPK in leiomyoma 
versus myometrial tissue. This is most likely due to significant phospho-p44/42 MAPK 
expression being phase specific and could be missed if tissues from the two phases are 
pooled. 
In breast cancer cells, phospho-p44/42 MAPK has been found to phosphorylate 
the ER at serine 118 in response to estrogen [15]. In this study, we found higher 
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expression and colocalization of phospho-p44/42 MAPK and ERa-phospho-Serl 18 in 
leiomyomas from the proliferative phase, which is the phase of the cycle where estrogen 
is the dominating hormone. These data imply that in leiomyomas, phospho-p44/42 
MAPK may be the kinase that phosphorylates ERa at serine 118 and this 
phosphorylation may be enhanced during the proliferative phase by estrogen. 
Previously in our laboratory, we found PCNA expression to be significantly 
higher in leiomyomas than in matched myometrial samples [13]. In this study PCNA 
expression was also significantly higher in leiomyomas than in matched myometrial 
samples. On average, PCNA labeling was 0.77% in the myometrium and 23.49% in 
leiomyomas. PCNA labeling of cells in tumors from women in the proliferative phase 
(28.60%) was significantly higher compared to tumors from women of the secretory 
phase (18.39%). These data show that leiomyomas proliferate at a higher rate than 
normal myometrium and that proliferation occurs at a higher rate in tumors from the 
proliferative phase compared to the secretory phase of the menstrual cycle. The PCNA 
labeling indices in this study were higher compared to the values from a previous study, 
which was most likely due to the increased sensitivity of the antibody used in this study 
compared to our earlier studies. More importantly, however, the overall trend of 
increased PCNA labeling in leiomyomas versus myometria, and increased labeling of 
proliferative phase tumors versus secretory phase are in agreement with our earlier 
findings and others, respectively [13, 38]. Also, although PCNA labeling was increased 
overall in the leiomyomas, there was variation of PCNA expression between tumors from 
the same woman which supports the importance of hormones in up-regulating or down-
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regulating local cytokines and growth factors that may in turn control autonomous tumor 
growth. 
Our previous studies have shown that ERa-phospho-Serl 18 is significantly 
expressed more in leiomyoma tissues from the proliferative compared to the secretory 
phase of the menstrual cycle. We also showed evidence by colocalization and 
immunoprecipitation using in vivo studies that phospho-p44/42 MAPK may be 
phosphorylating ERa at serine 118 and this phosphorylation may be enhanced in the 
proliferative phase. In vitro studies were conducted to determine if phospho-p44/42 
MAPK is phosphorylating ERa at serine 118 and how this phosphorylation is regulated 
by E2 and P4 in the menstrual cycle phases. In UtLM cells, the expression of ERa-
phospho-Serl 18 was found to be significantly higher when treated with hormones 
representing the proliferative (E2 dominant) compared to the secretory (P4 dominant) 
phase of the menstrual cycle and when treated with excess E2 versus P4, alone. Also, in 
UtLM cells, ERa-phospho-Serl 18 and phospho-p44/42 MAPK protein expression levels 
were significantly reduced when the cells were treated with the MAPK inhibitor 
PD98059. These data suggest that in uterine leiomyoma cells, phospho-p44/42 MAPK 
phosphorylates ERa at serine 118 and that this phosphorylation is upregulated by the 
proliferative phase hormones in. In breast and endometrial cancer cells, ERa is 
phosphorylated at Serl 18 in the presence of estrogen [44, 50]. In breast cancer cells 
phospho-p44/42 MAPK can phosphorylate ERa at serine 118 in the presence and 
absence of estradiol. Currently no other studies have been identified that observed the 
regulation of ERa-phospho-Serl 18 expression by progesterone in addition to estrogen in 
uterine leiomyomas. In our previous study, we observed less ERa-phospho-Serl 18 
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protein expression in leiomyomas from the secretory phase compared to the proliferative 
phase [32]. In breast cancer tumors, ERa-phospho-Serl 18 expression was more 
frequently observed in progesterone receptor-positive tumors compared with 
progesterone receptor-negative tumors [50]. These results demonstrate that the 
expression of ERa-phospho-Serl 18 is regulated by estrogen and progesterone. Also, in 
this study we show more association of ERa-phospho-Serl 18 and phospho-p44/42 
MAPK in UtLM cells treated with hormones representing the proliferative phase 
compared to the secretory phase of the menstrual cycle. These data further imply that in 
uterine leiomyoma cells phospho-p44/42 MAPK phosphorylates ERa at serine 118 and 
that this phosphorylation is enhanced by the proliferative phase hormones. Prior to our 
recent study, there were no other reports that show the effects of E2 and P4 on 
phosphorylation of ERa at serine 118 by phospho-p44/42 MAPK in uterine leiomyomas. 
In this study, we also determined how clinical compounds such as raloxifene and 
asoprisnil could regulate phosphorylation of ERa at serine 118 in uterine leiomyoma 
cells. We found raloxifene decreased E2-induced ERa-phospho-Serl 18 protein 
expression in UtLM cells and inhibited UtLM cell growth. These results demonstrated 
that phosphorylation of ERa at serine 118 may be a mechanism whereby raloxifene can 
inhibit E2-induced leiomyoma growth in vivo. Currently, there are no other studies that 
show estrogen receptor phosphorylation regulated by the clinical compounds raloxifene 
and/or asoprisnil in uterine leiomyomas. Lipfert et al. have demonstrated that 
phosphorylation of the ERa at serine 118 is induced in breast and endometrial cancer 
cells by E2 and raloxifene. In a study using human primary uterine leiomyoma cells 
raloxifene at 10"9 M inhibited leiomyoma cell growth, whereas raloxifene at 10"8 M and 
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10"7M promoted leiomyoma growth [45]. Although in both mine, and Liu et al. study the 
concentration of raloxifene was 10"9M, our study shows that raloxifene stimulates fibroid 
growth compared to control as oppose to Liu et al. study that showed raloxifene inhibited 
leiomyoma growth. The discrepancy between these results might be due to the 
differences in the cells that were used for the studies. In the study by Liu et al, primary 
leiomoyoma cells were obtained from twelve uterine leiomyoma tissues taken from 
different women, which can cause the cells to have different responses to raloxifene. In 
this study a uterine leiomyoma cell line that is commercially available and well 
characterized was used [13]. Also, raloxifene is a selective estrogen receptor modulator 
(SERM) like its sister compound tamoxifen, which, is used as a preventive agent against 
breast cancer [5]. Tamoxifen has been found to induce endometrial cancer and 
leiomyosarcoma in women taking it for breast cancer [5, 6]. So it appears that there is 
duplicity in the responses of tamoxifen in that, in the breast it is an antagonist, but in the 
uterine endometrium and possible myometrium it can be an agonists depending on tissue 
and cell type. Also, when you look at the proliferation data of UtLM cells, Ral is 
stimulatory compared to the VC, but it does significantly decrease the stimulatory effects 
of E2, based on the statistical analysis when you compare E2 and E2 + Ral. This 
inhibitory effect of Ral when compared to E2 is observed probably because when E2 the 
natural ER ligand and Ral, the ER modulator is used in combination with each other, they 
may cause desensitization and down regulation of the ER thereby causing less receptor to 
be available for phosporylation. 
In this study asoprisnil did not have any effects on phosphorylation of ERa at 
serine 118 in UtLM and UtSMC cells and the growth of these cells (Fig. 15a and 17a). 
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Previous studies have shown that asoprisnil can decrease cell proliferation of cultured 
leiomyoma cells compared to controls and have no effects on cultured myometrial cells 
[16, 52]. The differences in the results of these studies may be due to the use of primary 
leiomyoma cells where there is extensive variability from sample to sample, compared to 
a well-established leiomyoma and characterized leiomyoma cell line used in this study. 
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CHAPTER V 
SUMMARY 
In summary, the mechanisms whereby ER and growth factor signaling pathways 
interact and promote leiomyoma growth is not known and has not been widely studied. 
In the tissue studies, we found that ERa-phospho-Serl 18 protein expression levels were 
significantly increased in leiomyomas compared to myometrial tissues from both the 
proliferative and secretory phase of the menstrual cycle. Phospho-p44/42 MAPK protein 
was significantly expressed higher in leiomyomas taken from women in the proliferative 
phase of the menstrual cycle compared to myometrial tissue samples. ERa-phospho-
Serl 18 and phospho-p44/42 MAPK was found to be highly co-expressed and associated 
in leiomyomas compared to myometrial tissue from women in the proliferative phase. In 
addition, leiomyomas from the proliferative phase had significantly increased PCNA 
labeling compared to patient-matched myometrial tissue samples, and tumors from the 
secretory phase. Overall these finding show that there is "crosstalk" between the ER and 
growth factor pathways. Also, these data show that ERa may be phosphorylated by 
phospho-p44/42 MAPK at Ser-118 and possibly play an important role in the growth of 
fibroids. Additionally, the expression of ERa-phospho-Serl 18 may be, in part, 
upregulated by E2, which is the dominating hormone in the proliferative phase of the 
menstrual cycle. 
Our in vitro studies showed ERa-phospho-Serl 18 protein expression was 
significantly increased in leiomyoma cells treated with the proliferative versus the 
secretory phase hormones. Also, ERa-phospho-Serl 18 and phospho-p44/42 MAPK 
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protein expression was reduced in leiomyoma cells after treatment with the MAPK 
inhibitor PD98059. These previous findings were verified when increased protein 
expression of ERa-phospho-Serl 18 and phospho-p44/42 MAPK were found in tumor 
cells treated with excess E2 versus treatment with excess P4 and treatment in the presence 
of PD98059. Also, the in vitro studies showed more association and co-expression of 
ERa-phospho-Serl 18 and phospho-p44/42 MAPK proteins in leiomyoma cells treated 
with proliferative versus secretory phase hormones. These in vitro studies demonstrated 
that in uterine leiomyoma cells phospho-p44/42 MAPK phosphorylates ERa at serine 
118 and this phosphorylation was increased by the proliferative phase (E2 dominant 
phase) hormones. 
Prior to our recent publication, the pathways involved in phosphorylation of ERa 
in uterine leiomyomas have not been studied. In Fig. 18 we propose a possible 
mechanism of interaction between the ERa and growth factor signaling pathways and the 
regulation of these pathways by estradiol (E2) and progesterone (P4), which are highly 
supported by the tissue and in vitro studies reported. This schematic shows that 
activation of ERa via phosphorylation at serine 118 by phospho-p44/42 MAPK is 
regulated by E2 (positively) and P4 (positively or negatively) through the up or down-
regulation of local cytokines and growth factors. 
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Fig. 19 Proposed pathway for the interaction between ERa and growth factor signaling pathways in 
uterine leiomyomas. The ERa is activated by classical E2 binding and/or by phosphorylation at serine 118 
by activated MAPK. Activated ERa then activates gene transcription and translation of a GF. The GF will 
bind to its receptor (GFR) and the activated GFR will in turn activate the MAPK pathway, which can result 
in proliferation and also, possible phosphorylation of ERa at serine 118. E2 can up-regulate GFs and GFRs 
with an increase in downstream MAPK activation and possible ERa -phospho-Serl 18 phosphorylation; 
whereas, P4 can decrease or increase ERa, GF, and GFR production, which in turn results in up or down 
regulation of activated MAPK and ERa -phospho-Serl 18 expression. 
Lastly, we observed the effects of raloxifene and asoprisnil in the presence and 
absence of E2 and P4 on ERa-phospho-Serl 18 protein expression and leiomyoma cell 
proliferation. To date, this is the first study that shows the effects of raloxifene and 
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asoprisnil on phosphorylation of ERa at serine 118 in leiomyomas cells. We found that 
E2 increased leiomyoma proliferation and enhanced ERa-phospho-Serl 18 protein 
expression in leiomyoma cells. Raloxifene was shown to decrease E2-induced ERa-
phospho-Serl 18 expression and leiomyoma cell proliferation. This data suggest that 
decreasing the phosphorylation of ERa at serine 118 may be involved in the mechanisms 
by which raloxifene can reduce leiomyoma cell proliferation. Our data in this study also 
showed that asoprisnil has no affect on ERa phosphorylation at serine 118 and growth of 
leiomyoma cells. 
To date, this is the only study that examined the "crosstalk" between ERa and a 
growth factor pathway via phosphorylation. These studies provide a better understanding 
of the specific mechanism involved in uterine leiomyoma ERa phosphorylation by the 
MAPK pathway. This project also describes one mechanism by which raloxifene 
modulates leiomyoma cell growth. The results of this study provides more critical 
information about the mechanisms involved in uterine leiomyoma growth which, in turn, 
will assist in the development of non-invasive medicinal treatments for this disease. 
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